Ogkologos | Ogkologos.com | Page 49

Home Authors Posts by Ogkologos

4396 POSTS 0 COMMENTS

Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo...

Ogkologos - June 10, 2025

FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma

Ogkologos - June 6, 2025

Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC

Ogkologos - June 6, 2025

ESMO Gynaecological Cancers Congress 2025, Vienna, Austria, 19-21 June

Ogkologos - June 5, 2025

EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab

Ogkologos - June 5, 2025

Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients...

Ogkologos - June 4, 2025

Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and...

Ogkologos - June 3, 2025

Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced...

Ogkologos - June 2, 2025

FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib...

Ogkologos - May 30, 2025

EMA Adopts a Positive Opinion for Biosimilar Denosumab

Ogkologos - May 28, 2025

1...484950...440 Page 49 of 440

MOST POPULAR

Bus Driver Finds Out Teen With Cancer Can’t Afford Prom &...

June 19, 2019

FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast...

May 13, 2026

¿Tener paneles solares o vivir cerca de una granja solar puede...

April 6, 2023

Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in...

April 11, 2022

HOT NEWS

Researchers Have Harnessed a Compound from a Common Plant Called Feverfew...

Patients Diagnosed with Cancer During Pregnancy May Have Increased Risk of...

Stem cell research: meet the scientist growing ‘mini guts’ in her...

Zanidatamab Demonstrates Meaningful Clinical Benefit with a Manageable Safety Profile in...